A Proven Team of Industry Leaders and Innovators


Founded in 2018, Sandhill Therapeutics has harnessed the power of Natural Killer (NK) cells and innate T cell populations to maximize tumor killing and to provide a cost-effective, universal, immediately available, cellular immuno-oncology therapy.

  • More than 150 combined years of experience in translation, product development, clinical development, manufacturing, and regulatory in the cell/gene therapy space
  • Product and clinical experience in both autologous and allogeneic cell/gene therapies
  • Experience with cGMP and GCP regulatory activities; participated in EMA submission for ATMP product
  • Network of cell/gene therapy resources ready to develop commercially attractive off-the-shelf cellular immuno-oncology therapeutics



Sandhill Team

Card image

Annemarie Moseley MD PhD
CEO, Director

Card image

RA Session II
Director

Card image

Henri Boodée MD MBA
VP Clinical Development & Medical Affairs

Card image

Cassandra Harrison MPH MBA
VP Clinical Operations &
Data Management

Card image

Jian Chen MD PhD
Director for Translational Research

Card image

Ken Moseley JD
Legal, Director

Card image

Richard Turner PhD
Consultant, CMC

Card image

Natalie Thomas PhD
Consultant, Preclinical